Skip to main content
. Author manuscript; available in PMC: 2015 Feb 19.
Published in final edited form as: Cancer Res. 2012 Aug 3;72(19):4909–4919. doi: 10.1158/0008-5472.CAN-12-2194

Figure 5.

Figure 5

Examination of the role of BCL2A1 in intracranial tumor growth. A, RT-PCR examination of BCL2A1 in clinical samples of melanoma CNS metastases. B, mice implanted orthotopically with 6-4BCL2A1 cells showed more aggressive spontaneous metastatic disease leading to a shorter median survival. C, the overexpression of BCL2A1 did not lead to a significant increase in incidence of metastatic disease in various organs. D to F, intracranially implanted 6-4BCL2A1 cells gave rise to larger intracranial melanomas when compared with 6-4vector cells.